Abstract:The worldwide prevalence of pancreatic cancer has been rising in recent decades, and its prognosis has not improved much. The imbalance of substance and energy metabolism in tumour cells is among the primary causes of tumour formation and occurrence, which is often controlled by the neuroendocrine system. We applied Cox and LASSO regression analysis to develop a neuroendocrine regulation- and metabolism-related prognostic risk score model with three genes (GSK3B, IL18 and VEGFA) for pancreatic cancer. TCGA dataset served as the training and internal validation sets, and GSE28735, GSE62452 and GSE57495 were designated as external validation sets. Patients classified as the low-risk population (category, group) exhibited considerably improved survival duration in contrast with those classified as the high-risk population, as determined by the Kaplan-Meier curve. Then, we combined all the samples, and divided them into three clusters using unsupervised clustering analysis. Unsupervised clustering, t-distributed stochastic neighbor embedding (t-SNE), and principal component analysis (PCA) were further utilized to demonstrate the reliability of the prognostic model. Moreover, the risk score was shown to independently function as a predictor of pancreatic cancer in both univariate and multivariate Cox regression analyses. The results of gene set enrichment analysis (GSEA) illustrated that the low-risk population was predominantly enriched in immune-associated pathways. "ESTIMATE" algorithm, single-sample GSEA (ssGSEA) and the Tumor Immune Estimation Resource (TIMER) database showed immune infiltration ratings were enhanced in the low-risk category in contrast with the high-risk group. Tumour immune dysfunction and exclusion (TIDE) database predicted that immunotherapy for pancreatic cancer may be more successful in the high-risk than in the low-risk population. Mutation analysis illustrated a positive link between the tumour mutation burden and risk score. Drug sensitivity analysis identified 44 sensitive drugs in the high- and low-risk population. GSK3B expression was negatively correlated with Oxaliplatin, and IL18 expression was negatively correlated with Paclitaxel. Lastly, we analyzed and verified gene expression at RNA and protein levels based on GENPIA platform, HPA database and quantitative real-time PCR. In short, we developed a neuroendocrine regulation- and metabolism-associated prognostic model for pancreatic cancer that takes into account the immunological microenvironment and drug sensitivity.

Patterns and Predictors of Pancreatic Neuroendocrine Tumor Prognosis: Are No Two Leaves Alike?

A Prognostic Nomogram in Patients with Distant Metastasis of Pancreatic Neuroendocrine Tumors: a Population-Based Study.

Analysis of clinical characteristics and prognosis of 63 cases of pancreatic neuroendo-crine tumor

Predicting Liver Metastasis in Pancreatic Neuroendocrine Tumor After Surgery: A Population-Based Study

The Prognostic Value of Multidetector CT Features in Predicting Overall Survival Outcomes in Patients with Pancreatic Neuroendocrine Tumors.

[The Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms].

Analysis of Risk Factors Affecting the Prognosis of Pancreatic Neuroendocrine Tumors

Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer

Prognostic Value and Clinical Predictors of Lymph Node Metastases in Pancreatic Neuroendocrine Tumors

Clinical and CT Quantitative Features for Predicting Liver Metastases in Patients with Pancreatic Neuroendocrine Tumors: A Study with Prospective/External Validation

Prognostic Factors of Long-Term Outcome in Surgically Resectable Pancreatic Neuroendocrine Tumors: A 12-Year Experience from A Single Center

Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies

A Combined Nomogram Model to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors.

Construction and Validation of a Nomogram for Patients with Pancreatic Neuroendocrine Tumors: A Population Study of 5,927 Patients

Characterization of neuroendocrine regulation- and metabolism-associated molecular features and prognostic indicators with aid to clinical chemotherapy and immunotherapy of patients with pancreatic cancer

Developing a Predictive Model for Metastatic Potential in Pancreatic Neuroendocrine Tumor

The prognostic and therapeutic value of the tumor microenvironment and immune checkpoints in pancreatic neuroendocrine neoplasms

Clinical Outcomes and Prognostic Factors of Resected Pancreatic Neuroendocrine Neoplasms: A Single-Center Experience in China.

Prognostic biomarkers of pancreatic cancer identified based on a competing endogenous RNA regulatory network

Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model